Evaluation of glycemic control in type 2 diabetes patients using Diafree juice

Submission date	Recruitment status	Prospectively registered
03/07/2025	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
29/07/2025	Completed	☐ Results
Last Edited	Condition category	Individual participant data
25/07/2025	Nutritional, Metabolic, Endocrine	[X] Record updated in last year

Plain English summary of protocol

Background and study aims

This study aims to assess how effective a herbal product called Diafree Juice is in helping people with type 2 diabetes manage their blood sugar levels. Diafree Juice is an Ayurvedic formulation already being used by patients as part of their regular diabetes care. The study analyzes anonymized health data shared by physicians to understand if Diafree Juice leads to improvements in two key measures of blood sugar: HbA1c and post-meal glucose levels.

Who can participate?

People diagnosed with type 2 diabetes, aged 18 years or older, with HbA1c values between 5.5% and 7% who have already been prescribed Diafree Juice by their doctor as part of routine treatment.

What does the study involve?

There is no direct involvement from patients. Doctors who are already treating these individuals shared anonymized health records, including blood sugar levels before and after the use of Diafree Juice. The study does not require any new medication, lab tests, or visits.

What are the possible benefits and risks of participating?

There are no direct risks or benefits to the patients included in this study. Since the study only uses anonymized data that was already collected as part of routine care, there is no additional burden or intervention for patients. The results of this study may help inform future research and improve clinical understanding of the product's role in diabetes management.

Where is the study run from?

The study is coordinated by the Kapiva Academy of Ayurveda in Bengaluru, India, using data collected from Ayurvedic doctors across the country.

When is the study starting and how long is it expected to run for? April 2024 to December 2024

Who is funding the study?

The study is funded and sponsored by Adret Retail Private Limited (Kapiva Ayurveda), based in Bengaluru, India.

Who is the main contact? Dr Anushri Shah, anushri.shah@kapiva.in

Contact information

Type(s)

Scientific, Principal Investigator

Contact name

Dr Anushri Shah

Contact details

KAPIVA ACADEMY OF AYURVEDA, 118/2 Doddakannenahalli Village,Varthur Hobli, Sarjapur - Marathahalli Rd, Next to August grand Apartments
Bengaluru, Karnataka
India
560035
+91 8588825824
anushri.shah@kapiva.in

Type(s)

Public

Contact name

Dr Prachi Sharma

Contact details

Digicare Healthcare Solutions Private Limited Ahmedabad India 380058 +91 8290799906 patientsafety@tatvacare.in

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

KAA/RD/PMS-DF/2024/001

Study information

Scientific Title

Evaluating the effect of Diafree Juice on blood sugar control in type 2 diabetes: a retrospective study

Study objectives

Diafree Juice reduces HbA1c and postprandial plasma glucose (PPBG) in patients with type 2 diabetes mellitus over a 12-week period.

Ethics approval required

Ethics approval not required

Ethics approval(s)

Study design

Open-label prospective single-arm observational

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Medical and other records

Study type(s)

Treatment

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Type 2 Diabetes Mellitus

Interventions

Participants included in this study were individuals with type 2 diabetes who had already been prescribed Diafree Juice by their treating physicians as part of routine care. The study did not involve any new intervention, enrolment, or patient contact. Physicians shared anonymized clinical data for eligible patients, including HbA1c and postprandial plasma glucose (PPBG) levels at baseline (prior to Diafree Juice initiation) and after approximately 12 weeks (84 days) of continued product use. No additional follow-up or study procedures were required beyond standard medical care. The total duration of observation per patient was 12 weeks.

Intervention Type

Other

Primary outcome measure

HbA1c level measured using laboratory test results reviewed from patient medical records maintained by treating physicians at Baseline (prior to Diafree Juice initiation) and after 12 weeks (Day 84)

Secondary outcome measures

Postprandial Plasma Glucose (PPBG) (mg/dL) measured using laboratory test results reviewed from patient medical records maintained by treating physicians at Baseline (prior to Diafree Juice initiation) and after 12 weeks (Day 84)

Overall study start date

01/04/2024

Completion date

31/12/2024

Eligibility

Key inclusion criteria

Diagnosed T2DM with HbA1c 5.5-7%

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

82

Total final enrolment

82

Key exclusion criteria

- 1. Type 1 DM, insulin therapy
- 2. Fluctuating OHA doses
- 3. Contraindication to herbal use

Date of first enrolment

15/04/2024

Date of final enrolment

27/12/2024

Locations

Countries of recruitment

India

Study participating centre Kapiva Academy of Ayurveda India 560103

Sponsor information

Organisation

ADRET RETAIL PRIVATE LIMITED (KAPIVA)

Sponsor details

No 16-1 and 17-2, Vaishnavi Tech Park, Ambalipura Village, Varthur Hobli, Varthur Bengaluru, Karnataka India 560103 +91 9481813428 govindarajan@kapiva.in

Sponsor type

Industry

Funder(s)

Funder type

Industry

Funder Name

ADRET RETAIL PRIVATE LIMITED (KAPIVA)

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal

Intention to publish date

10/12/2025

Individual participant data (IPD) sharing plan

Participant-level data will not be shared due to confidentiality and data protection policy. Only aggregate results will be disseminated.

IPD sharing plan summary

Not expected to be made available